LTFS
RNAC icon

Ladenburg Thalmann Financial Services’s Cartesian Therapeutics RNAC Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23
Closed -$11K – 5310
2018
Q3 		$11K Buy
+23
New +$9.24K ﹤0.01% 4247

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ladenburg Thalmann Financial Services's RNAC Position: Q4 2018 in Review

Ladenburg Thalmann Financial Services sold out of Cartesian Therapeutics (RNAC) in Q4 2018, closing a stake of 23 shares — an estimated $11K sold.

Ladenburg Thalmann Financial Services first reported a position in RNAC in Q3 2018 and held it in 1 quarter. The position peaked at $11K in Q3 2018. 54 funds tracked by Wall St. Rank hold RNAC as of Q4 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Cartesian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 23 Cartesian Therapeutics shares in Q4 2018, an estimated $11K.
  • Ladenburg Thalmann Financial Services first reported a position in Cartesian Therapeutics in Q3 2018 and held it in 1 quarter.
  • Ladenburg Thalmann Financial Services's Cartesian Therapeutics position peaked at $11K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2018, filed 14 Feb 2019.